Find Funding Opportunities

Notice Intent Publish Program Announcement Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21) Notice Number: NOT-NS-09-018 Key Dates Release Date: September 22, 2009 Issued National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) Purpose nbsp; National Institute Neurological Disorders Stroke NINDS) intends issue Program Announcement Special Referral Considerations PAR) the fall 2009 provide support exploratory developmental translational research therapeutics reducing mortality morbidity caused acute exposures chemical threat agents.  Chemical threat agents toxic chemicals could released a deliberate terrorist attack against civilians, by accident natural disaster causing mass casualties.  NIH CounterACT Research Program supports basic, translational, clinical research aimed the discovery and/or identification better therapeutic medical countermeasures against chemical threat agents, facilitates movement through regulatory process www.ninds.nih.gov/counteract).  CounterACT Exploratory/Developmental Projects Translational Research R21) be utilized support 1-2 year pilot studies generate tools proof-of-principle data therapeutics treat exposures chemical threats.  Chemical threats include traditional chemical warfare nerve agents such sarin VX, toxic industrial chemicals such cyanide chlorine, toxic agricultural chemicals such parathion sodium fluoroacetate.  Pilot studies include creation validation screening assays therapy development, identification candidate therapeutics, development preliminary proof-of-principle data the efficacy candidate therapeutics.  Four six awards anticipated, with direct costs limit 250,000 per year.  is anticipated several NIH Institutes, including National Eye Institute NEI), National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), National Institute Environmental Health Sciences NIEHS), the National Institute General Medical Sciences NIGMS), also participate this funding opportunity announcement. notice being provided allow potential applicants sufficient time develop responsive projects.  APPLICATIONS NOT BEING REQUESTED THIS TIME. Inquiries Direct inquiries regarding Notice to: David A. Jett, Ph.D. Program Director, NIH CounterACT Research National Institutes Health, NINDS 6001 Executive Blvd. NSC, Room 2177, MSC 9527 Bethesda, MD 20892-9527 Telephone: 301-496-6035 Fax: 301-402-1501 jettd@ninds.nih.gov

Notice Additional Information Applicants the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers U54) Program Notice Number: NOT-HD-09-023 Key Dates Release Date: September 16, 2009 Issued Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), http://www..nichd.nih.gov) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), http://www.niams.nih.gov) National Heart, Lung, Blood Institute NHLBI) http://www.nhlbi.nih.gov) National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov) Purpose purpose this Notice to alert potential applicants RFA-HD-09-027, ldquo;Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers U54)”, additional guidance available regarding content organization the applications.  Questions Answers document been posted the Wellstone Center website: http:// wellstonemdcenters.nih.gov . Potential applicants encouraged review document it provides clarification a number scientific technical issues the application process. Inquiries Additional questions be directed to: James W. Hanson, M.D. Director, Center Developmental Biology Perinatal Medicine Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) 6100 Executive Boulevard, Room 4A05A  Bethesda, MD 20892-7510 Telephone: 301) 496-8535 Email: hansonj@mail.nih.gov Glen H. Nuckolls, Ph.D. Director, Muscle Disorders Therapies Program Musculoskeletal Diseases Branch National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Democracy Plaza 6701 Democracy Boulevard, Suite 800 Bethesda, MD 20892-4872 Telephone: 301) 594-4974 Email: nuckollg@mail.nih.gov   John D. Porter, Ph.D. Program Director, Neurogenetics Cluster National Institute Neurological Disorders Stroke NINDS) 6001 Executive Blvd., Room 2142 Bethesda, MD 20892 Rockville, MD 20852 express/courier service) Telephone: 301) 496-5739 FAX: 301) 402-1501 Email: porterjo@ninds.nih.gov  Jonathan R. Kaltman, M.D. Heart Development Structural Diseases Branch Division Cardiovascular Diseases National Heart, Lung, Blood Institute NHLBI) Rockledge Center 6701 Rockledge Drive, Room 8222 Bethesda, MD 20892-7940 Zip Code 20817 express/courier service) Telephone: 301) 435-0510 FAX: 301-480-1454 Email: kaltmanj@nhlbi.nih.gov

RFA AMMENDMENT: Revised Review Criteria Ancillary Studies Immunomodulation Clinical Trials RFA–AI-08-011) Notice Number: NOT-AI-09-054 Key Dates Release Date: September 16, 2009 Issued National Institute Allergy Infectious Diseases NIAID) http://www.niaid.nih.gov) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) http://www.niams.nih.gov) National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) National Institute Diabetes Digestive Kidney Diseases NIDDK) http://www.niddk.nih.gov) Purpose purpose this notice to clarify the criteria below be used review applications submitted response RFA-AI-08-011 was extended a final receipt date January 9, 2010 NOT-AI-09-044): Overall Impact. Reviewers provide overall priority/impact score reflect assessment the likelihood the project exert sustained, powerful influence the research field(s) involved, consideration the following five core review criteria, additional review criteria applicable the project proposed).  Core Review Criteria.  Reviewers consider of five review criteria below the determination scientific technical merit, give separate score each.  application does need be strong all categories be judged likely have major scientific impact.  example, project by nature not innovative be essential advance field. Significance.  Does project address important problem a critical barrier progress the field?  the aims the project achieved, will scientific knowledge, technical capability, and/or clinical practice improved?  will successful completion the aims change concepts, methods, technologies, treatments, services, preventative interventions drive field? Investigator(s).  the PD/PIs, collaborators, other researchers well suited the project?  Early Stage Investigators New Investigators, they appropriate experience training?  established, they demonstrated ongoing record accomplishments have advanced field(s)?  the project collaborative multi-PD/PI, the investigators complementary integrated expertise; their leadership approach, governance organizational structure appropriate the project? Innovation. Does application challenge seek shift current research clinical practice paradigms utilizing novel theoretical concepts, approaches methodologies, instrumentation, interventions?  the concepts, approaches methodologies, instrumentation, interventions novel one field research novel a broad sense?  a refinement, improvement, new application theoretical concepts, approaches methodologies, instrumentation, interventions proposed? Approach.  the overall strategy, methodology, analyses well-reasoned appropriate accomplish specific aims the project?  potential problems, alternative strategies, benchmarks success presented?   the project in early stages development, the strategy establish feasibility will particularly risky aspects managed? the project involves clinical research, the plans 1) protection human subjects research risks, 2) inclusion minorities members both sexes/genders, well the inclusion children, justified terms the scientific goals research strategy proposed? there high likelihood the samples needed the proposed studies become available? Environment.  the scientific environment which work be done contribute the probability success?  the institutional support, equipment other physical resources available the investigators adequate the project proposed?  the project benefit unique features the scientific environment, subject populations, collaborative arrangements?  Additional Review Criteria. applicable the project proposed, reviewers consider following additional items the determination scientific technical merit, will give separate scores these items. Protections Human Subjects. research involves human subjects does involve of six categories research are exempt under 45 CFR Part 46, committee evaluate justification involvement human subjects the proposed protections research risk relating their participation according the following five review criteria: 1) risk subjects, 2) adequacy protection against risks, 3) potential benefits the subjects others, 4) importance the knowledge be gained, 5) data safety monitoring clinical trials. research involves human subjects meets criteria one more the six categories research are exempt under 45 CFR Part 46, committee evaluate: 1) justification the exemption, 2) human subjects involvement characteristics, 3) sources materials. Inclusion Women, Minorities, Children. the proposed project involves clinical research, committee evaluate proposed plans inclusion minorities members both genders, well the inclusion children. Vertebrate Animals. committee evaluate involvement live vertebrate animals part the scientific assessment according the following five points: 1) proposed of animals, species, strains, ages, sex, numbers be used; 2) justifications the of animals for appropriateness the species numbers proposed; 3) adequacy veterinary care; 4) procedures limiting discomfort, distress, pain injury that is unavoidable the conduct scientifically sound research including use analgesic, anesthetic, tranquilizing drugs and/or comfortable restraining devices; 5) methods euthanasia reason selection not consistent the AVMA Guidelines Euthanasia. Biohazards. Reviewers assess whether materials procedures proposed potentially hazardous research personnel and/or environment, if needed, determine whether adequate protection proposed. Inquiries Inquiries discussion plans responding RFA–AI-08-011 strongly encouraged. Interested parties contact: 1. Scientific/Research Contact(s): Annette L. Rothermel, Ph.D. Division Allergy, Immunology Transplantation National Institute Allergy Infectious Diseases 6610 Rockledge Drive Room 6617, MSC-6601 Bethesda, MD 20892- 6601 Telephone: 301) 496-7104 Fax: 301) 480-1450 Email: arothermel@niaid.nih.gov   Yan Wang, M.D., Ph.D. Division Skin Rheumatic Diseases, Extramural Program National Institute Arthritis Musculoskeletal Skin Diseases National Institute Health, DHHS Democracy Plaza, Suite 800 6701 Democracy Blvd, MSC 4872 Bethesda, MD 20892 Phone: 301-594-5032 Fax: 301-480-1284 Email: wangy1@mail.nih.gov Ursula Utz, Ph.D. Program Director National Institute Neurological Disorders Stroke Room 2134 6001 Executive Boulevard Bethesda, MD 20892-9521 Phone: 301-496-1431 FAX: 301-402-1501 Email: utzu@mail.nih.gov Beena Akolkar, Ph.D. Division Diabetes, Endocrinology, Metabolic Diseases National Institute Diabetes Digestive Kidney Diseases Room 6105 6707 Democracy Boulevard Bethesda, MD 20892-5460 Phone: 301-594-8812 FAX: 301-480-3503 Email: akolkarb@niddk.nih.gov 2. Peer Review Contact(s): Paul Amstad, Ph.D. Division Extramural Activities National Institute Allergy Infectious Diseases Room 3121, MSC-7616 6700B Rockledge Drive Bethesda, MD 20892-7616 Bethesda, MD 20817 express mail) Telephone: 301) 402-7098 Fax: 301) 480-2408 Email: pamstad@niaid.nih.gov

Administrative Changes the Joint NIH-NSF Initiative - Collaborative Research Computational Neuroscience CRCNS) Notice Number: NOT-NS-09-017 Key Dates Release Date:  September 4, 2009 Receipt Date: nbsp; November 17, 2009 Issued National Science Foundation NSF) http://www.nsf.gov) Directorate Computer Information Science Engineering Directorate Biological Sciences Directorate Social, Behavioral, Economic Sciences Directorate Mathematical Physical Sciences National Institutes Health NIH) http://www.nih.gov) National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) National Institute Mental Health NIMH) http://www.nimh.nih.gov) National Institute Drug Abuse NIDA) http://www.nida.nih.gov) National Institute Deafness Other Communication Disorders NIDCD) http://www.nidcd.nih.gov) National Institute Alcohol Abuse Alcoholism NIAAA) http://www.niaaa.nih.gov) National Eye Institute NEI)  http://www.nei.nih.gov) National Institute Biomedical Imaging Bioengineering NIBIB) http://www.nibib.nih.gov) Notice an amendment NOTICE: NOT-NS-08-008 Purpose nbsp; Notice announces several administrative changes the joint initiative, Collaborative Research Computational Neuroscience CRCNS), among four National Science Foundation NSF) Directorates seven participating National Institutes Health NIH) Institutes. CRCNS announcement released under NSF 08-514 http://www.nsf.gov/pubs/2008/nsf08514/nsf08514.htm).  new NOTICE incorporates following administrative changes please note the goal the program, scientific areas, budget limits, review criteria funding process NSF NIH remain same): 1. DEADLINE CHANGE deadline proposals changed October 30, 2009, November 17, 2009. 2. POSTDOCTORAL MENTORING PLANS proposal requests funding support postdoctoral researchers must include description the mentoring activities will provided such individuals. Proposals do comply this requirement be returned without review. nbsp;Please http://www.nsf.gov/pubs/policydocs/pappguide/nsf09_29/gpg_2.jsp#IIC2j further information. 3. FASTLANE, GRANTS.GOV announced May 21st, investigators must prepare submit proposals the NSF using NSF FastLane system http://www.fastlane.nsf.gov/.  NSF continue collaborate institutions have invested system-to-system submission functionality their preferred proposal submission method.  NSF plans provide web services interface those institutions want use existing grants management systems directly submit proposals NSF. 4. GERMAN-USA COLLABORATION COMPUTATIONAL NEUROSCIENCE NSF the German Federal Ministry Education Research BMBF) entered an agreement will enable US-German collaborative research proposals be considered through common review process.  more information, please NSF Dear Colleague Letter 09-60 http://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf0960) the Collaborative Research Computational Neuroscience program page http://www.nsf.gov/crcns/). Inquiries Prior the submission your proposal, written telephone inquiries NSF NIH program staff highly encouraged.  Please the NSF program announcement names contact information each the participating NSF Directorates and/or NIH Institutes http://www.nsf.gov/crcns/.

Notice Deadline Extension Program Announcement Bioengineering Research Grants Notice Number: NOT-EB-09-003 Update: following update relating this announcement been issued: September 29, 2009 - Notice NOT-CA-09-036 National Cancer Institute NCI) informs interested applicants it re-joined will continue participate this FOA. Key Dates Release Date: August 14, 2009 Issued National Eye Institute NEI), http://www.nei.nih.gov/) National Human Genome Research Institute NHGRI), http://www.genome.gov)  National Institute Alcohol Abuse Alcoholism NIAAA), http://www.niaaa.nih.gov) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), http://www.niams.nih.gov) National Institute Biomedical Imaging Bioengineering NIBIB), http://www.nibib.nih.gov)  National Institute Deafness Communication Disorders NIDCD), http://www.nidcd.nih.gov)  National Institute Dental Craniofacial Research NIDCR), http://www.nidcr.nih.gov)  National Institute Drug Abuse NIDA), http://www.nida.nih.gov) National Institute Environmental Health Sciences NIEHS), http://www.niehs.nih.gov)  National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), http://www.nichd.nih.gov) Purpose purpose this Notice to extend Expiration Date PA-07-279: Bioengineering Research Grants R01) until January 8, 2010.  following institutes no longer participating: National Cancer Institute NCI), http://www.nci.nih.gov) National Heart, Lung, Blood Institute NHLBI), http://www.nhlbi.nih.gov/) National Institute Allergy Infectious Diseases NIAID), http://www.niaid.nih.gov) National Institute Mental Health NIMH), http://www.nimh.nih.gov/) other aspects PA-07-279 remain unchanged. Inquiries Inquiries concerning Notice directed to: Albert Lee, Ph.D. National Institute Biomedical Imaging Bioengineering National Institutes Health 6707 Democracy Blvd., Suite 200 Bethesda, MD 20892-5477 Phone: 301) 451-4781 Email:  alee@mail.nih.gov 

Extended Expiration Date Program Announcement Exploratory/Developmental Bioengineering Research Grants R21) Notice Number: NOT-EB-09-004 Key Dates Release Date:  August 12, 2009 Issued National Eye Institute NEI), http://www.nei.nih.gov/) National Human Genome Research Institute NHGRI), http://www.genome.gov)  National Institute Alcohol Abuse Alcoholism NIAAA), http://www.niaaa.nih.gov) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), http://www.niams.nih.gov) National Institute Biomedical Imaging Bioengineering NIBIB), http://www.nibib.nih.gov)  National Institute Deafness Communication Disorders NIDCD), http://www.nidcd.nih.gov)  National Institute Dental Craniofacial Research NIDCR), http://www.nidcr.nih.gov)  National Institute Drug Abuse NIDA), http://www.nida.nih.gov)  National Institute Environmental Health Sciences NIEHS), http://www.niehs.nih.gov)  National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov) Purpose purpose this Notice to extend Expiration Date PA-06-418: Exploratory/Developmental Bioengineering Research Grants R21) until January 8, 2010.  following Institutes no longer participating: National Cancer Institute NCI), http://www.nci.nih.gov) National Heart, Lung, Blood Institute NHLBI), http://www.nhlbi.nih.gov/) National Institute Aging NIA) http:///www.nia.nih.gov) National Institute Mental Health NIMH), http://www.nimh.nih.gov/) other aspects PA-06-418 remain unchanged. Inquiries Inquiries concerning Notice directed to: Albert Lee, Ph.D. National Institute Biomedical Imaging Bioengineering National Institutes Health 6707 Democracy Blvd., Suite 200 Bethesda, MD 20892-5477 Phone: 301) 451-4781 Email:  alee@mail.nih.gov 

Notification NINDS Programmatic Priorities Use the K24 Midcareer Investigator Award Patient-Oriented Research Award Notice Number: NOT-NS-09-016 Key Dates Release Date: August 12, 2009 Issued National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov) Purpose purpose this notice to notify investigators programmatic priorities NINDS the of K24 award PA-09-037). K24 award, used NINDS, provides protected time mid-career, clinician-scientists act research mentors to expand own patient-oriented research. is enormous need mentoring junior clinician-scientists order increase pipeline clinicians successful research careers. number applications NINDS junior clinicians Career Development K) awards sharply decreasing, enhanced, large scale mentoring efforts be way reverse trend. Moreover, established clinical researchers in excellent position attract junior PhD scientists clinically-relevant, disease-oriented research. addition support mentoring, K24 provides protected time established clinician-scientists, dedicate time mentoring, expand own research new areas opportunities arise. notice serves only clarify programmatic priorities NINDS, also invite mid-career investigators an established dedication research mentoring join this effort attract promote entry junior scientists clinically significant neuroscience research.  Summary NINDS K24 support programmatic mentoring effort, combined a plan expand applicant’s research. will be awarded exclusively support on-going research efforts for mentoring is limited one’s own research area laboratory. accordance NIH guidelines, K24 be used protect between 25% 50% the applicant’s time. is expected the focus the application the majority the applicant’s effort the K24 be devoted the mentoring program.  Characteristics mentoring efforts high programmatic priority NINDS mentoring effort should tied a program research training. Programmatic activities might include, 1) research training mentoring residents fellows, 2) programs draw PhD neuroscientists disease-oriented research, 3) advising department’s trainees junior investigators grant submission grant writing, 4) advising network trainees junior investigators navigating pursuing successful, clinically-oriented research career 5) development and coordination courses related clinical research neurobiology disease. Although population being mentored include members the applicant’s own research program, should consist primarily this cohort. applicant should a well-established, mid-career investigator combines exceptional research clinical skills. Although is generally considered be somebody the Associate Professor level, mid-career applicants the Full Professor level also welcome apply. Applicants must hold R01 equivalent funding be actively involved running robust research program. applicant’s research program be completely clinical, it consist disease-focused laboratory research a patient-oriented component.  applicant must endorsed the Department Chair fulfilling mentorship role proposed. Chair should acknowledge, a letter support, the applicant be considered department’s overall mentor, coordinator, the program described. example, applicant be designated the departmental mentor research training residents fellows. role might include oversight over NINDS R25 program support residents fellows neurology neurosurgery http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-09-001.html, see subsequent reissue), the department such award. is anticipated there be only K24 recipient any time per department, unless department large and/or multiple, substantial programmatic efforts require multiple overseeing mentors. Research support through K24 Whereas mentoring component the K24 of extremely high priority NINDS, is also critical the K24 awardee maintain enhance already vigorous research program. Consequently, portion the K24 effort should into expanding and/or enhancing applicant’s research. effort include adding new component an already existing research project it be directed towards new, highly significant research area. Ideally, effort help generate new data will open a new area research the applicant, it allow applicant obtain new research training is necessary remain the forefront a research area. Although K24 be used directly support research component, NINDS does require a new research area proposed. However, salary support requested conduct research, proposed research must different what currently supported. is expected applicants have significant research support outside the K24, typically R01 equivalent, at least 3 the 5 years this award. Evaluation progress Applicants strongly encouraged provide detailed set measurable goals are anticipated be achieved year the K24 award regard both mentoring research. Particularly regard the mentoring component, applicants should provide description the proposed outcome the K24 support the metric(s) which achievement this outcome be measured. example, applicants indicate many trainees be mentored, specifically activities trainees participate that not occur without K24, planned outcome this mentorship e.g. next career steps the trainees, individual grant applications, etc.), timeline which applicant expects submit new research grant applications, courses will developed how trainees expected participate, many PhD degree holders students transition disease-related research how will measured, etc. choice metrics activities up the applicant, there should a clear description expected outcomes the K24 support. the NINDS K24 not awarded At NINDS, K24 award not made solely the benefit the PI’s on-going research solely support mentoring directly related the PI’s on-going research projects. research effort the applicant, the mentoring postdoctoral fellows working the applicant, covered the research funding already obtained the applicant, is an appropriate justification obtaining K24 support. K24 award does support mentoring clinical training is solely awarded promote mentoring research. Financial support the K24 award supply salary fringe the PI support mentoring activities course development tuition], travel, etc.). the application proposes expansion research area, which is current R-type funding, support also requested the new research area. K24 support not provided pay mentee’s salaries work projects currently funded R-type research awards. level funding provided described the institute contact web page accessed through program announcement. Inquiries Direct questions this Notice to: Stephen J. Korn, Ph.D. Director Training Career Development NIH/NINDS Neuroscience Center, Room  2186 6001 Executive Blvd MSC 9531 Bethesda, MD 20892-9531 e-mail: korns@ninds.nih.gov

Change NINDS Policy Regarding Salary Support Individual Mentored Career Development K) Awards Applicants Receive R01 Notice Number: NOT-NS-09-015 Update: following update relating this announcement been issued: 18, 2012 - Notice NOT-NS-12-018. Change NINDS salary caps the K02, K08 K23 Career Development Awards. Key Dates Release Date: August 7, 2009 Issued National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov) Purpose purpose this notice to notify investigators a change salary support provided 5 year mentored K awards the applicant obtains NIH R01 during first 3 years the award. Awards affected this notice the NINDS K01, K08, K23 K25 K Kiosk). Current Policy Mentored K awards require commitment at least 75% full time professional effort 50% effort neurosurgeons) towards mentored K research project. NINDS currently provides salary support commensurate the requested effort, to maximum 85,000. Applicants not obtain salary support other federal grants until final years mentored K support NOT-OD-08-065). the final years the K award, the awardee obtains federal grant is NIH R01 equivalent, applicants 1) reduce effort the K award a minimum 50% 2) obtain salary support, commensurate committed effort, the R01 equivalent federal grant. NINDS encourages K awardees obtain R01 level funding soon possible after obtaining mentored K. Consequently, K awardees obtain R01 federal equivalent during first 3 years a 5 year mentored K award be unable fully support salary commensurate their effort. Change Policy ameliorate situation, NINDS instituting following policy, effective the beginning FY2010. NINDS eliminate salary cap those mentored K awards obtain R01 equivalent federal grant funding during first 3 years the mentored K award. Applicants within first 3 years a mentored K award, obtain R01 federal equivalent, obtain to 80% their institutional base salary, commensurate effort, long the R01 research project represents expansion the K award project. minimum 75% effort must still devoted the K award project during first 3 years K award support. level salary support continue all remaining years the K award, commensurate effort devoted the K award project. During final years the mentored K award, additional salary be obtained the awarded R01, from another R01, effort exceeding 80% level. appropriate desired, level effort the mentored K award be reduced a minimum 50% during last years the award. all times, salary obtained the K award cannot exceed which commensurate full time professional effort committed the K award research project. those initially obtain R01 federal equivalent support during final 2 years mentored K award, salary support the mentored K award continue be capped up 85,000. accordance present NIH policy, additional salary support also obtained the awarded R01 federal equivalent. Timing the change salary support after receipt an R01 federal equivalent Grant start dates determine the salary change go effect.  the R01 obtained during same fiscal year the mentored K award anniversary date, requested salary change be effective the start date the R01. the R01 obtained the fiscal year subsequent the most recent mentored K award anniversary date, requested salary change be effective the K award anniversary date during fiscal year coincides the R01 start date example, the K award anniversary date July 1 the R01 approved the subsequent October council, salary change go effect the following July 1). is incumbent upon K award recipient request change salary support a timely manner. request changes K award salary must made least month prior the end the fiscal year which are take effect. Otherwise, changes the K award cannot made until K award anniversary date the subsequent fiscal year. Inquiries Direct questions this Notice to: Stephen J. Korn, Ph.D. Director Training Career Development NIH/NINDS Neuroscience Center, Room  2186 6001 Executive Blvd MSC 9531 Bethesda, MD 20892-9531 e-mail: korns@ninds.nih.gov

Extension Amendment the Receipt Date RFA–AI-08-011, Ancillary Studies Immunomodulation Clinical Trials R01) Notice Number: NOT-AI-09-044 Key Dates Release Date: June 16, 2009 Receipt Date(s): July 9, 2009, September, 9, 2009, November 9, 2009, January 9, 2010 Issued National Institute Allergy Infectious Diseases NIAID) http://www.niaid.nih.gov) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) http://www.niams.nih.gov) National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov) National Institute Diabetes Digestive Kidney Diseases NIDDK) http://www.niddk.nih.gov) Purpose purpose this notice to:  extend expiration date RFA AI-08-011, Ancillary Studies Immunomodulation Clinical Trials R01), June 10, 2009 January 10, 2010 change receipt dates monthly every-other-month, beginning July 9, 2009 provide NIAMS, NINDS, NIDDK staff contact information under Scientific Research Contacts” participating NIH Institutes intend commit approximately 2M FY2010 fund 4-5 new grants support ancillary immune mechanistic studies conjunction independently supported clinical trials a) immunomodulatory interventions immune system mediated diseases b) vaccines non-HIV/AIDS infectious diseases. than changes noted above, aspects RFA–AI-08-011 remain unchanged. Inquiries Inquiries discussion plans responding RFA AI08-011 strongly encouraged. Interested parties contact: Annette L. Rothermel, Ph.D. Division Allergy, Immunology Transplantation National Institute Allergy Infectious Diseases 6610 Rockledge Drive Room 3020, MSC-6601 Bethesda, MD 20892- 6601 Telephone: 301) 496-7104 Fax: 301) 480-1450 Email: arothermel@niaid.nih.gov   Yan Wang, M.D., Ph.D. Division Skin Rheumatic Diseases, Extramural Program National Institute Arthritis Musculoskeletal Skin Diseases National Institute Health, DHHS Democracy Plaza, Suite 800 6701 Democracy Blvd, MSC 4872 Bethesda, MD 20892 Phone: 301-594-5032 Fax: 301-480-1284 Email: wangy1@mail.nih.gov Ursula Utz, Ph.D. Program Director National Institute Neurological Disorders Stroke Room 2134 6001 Executive Boulevard Bethesda, MD 20892-9521 Phone: 301-496-1431 FAX: 301-402-1501 Email: utzu@ninds.nih.gov Beena Akolkar, Ph.D. Division Diabetes, Endocrinology, Metabolic Diseases National Institute Diabetes Digestive Kidney Diseases Room 681, MSC-5460 6707 Democracy Boulevard Bethesda, MD 20892-5460 Phone: 301-594-8812 FAX: 301-480-3503 Email: akolkarb@niddk.nih.gov

Administrative Supplements Collaboration the NIH-funded NeuroMab Facility Generate Monoclonal Antibodies Studies the Developing Nervous System Notice Number: NOT-NS-09-014 Key Dates Release Date:  June 11, 2009    Receipt Date:  July 17, 2009 Earliest Anticipated Start Date: September 1, 2009 Issued National Institute Neurological Disorders Stroke NINDS) http://www.ninds.nih.gov/) National Institute Mental Health NIMH) http://www.nimh.nih.gov) National Institute Deafness Other Communication Disorders NIDCD) http://www.nidcd.nih.gov) National Institute Alcohol Abuse Alcoholism NIAAA) http://www.niaaa.nih.gov/) National Institute Drug Abuse NIDA) http://www.nida.nih.gov) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) http://www.nichd.nih.gov) Purpose NINDS, NIMH, NIDCD, NIAAA, NIDA NICHD announce administrative supplement program 400,000 Fiscal Year 2009 provide funds NINDS, NIMH, NIDCD, NIAAA, NIDA NICHD-funded research projects provide resources the generation use monoclonal antibodies mAbs) useful the neurodevelopment community.  purpose this program to facilitate production new monoclonal antibodies NeuroMabs) targets high relevance studies the developing nervous systems animal models.  Background NeuroMab Facility established provide inexpensive, carefully verified monoclonal antibodies proteins the mammalian nervous system.  investigator-initiated antibody requests, facility enters a collaborative partnership which requesting investigator provide expertise reagents necessary the project.  a current list neurodevelopmental protein targets, click here.  Investigators suggest own protein targets provided suitable monoclonal antibodies these targets not exist.  of criteria consideration antibody requests the ability the collaborating investigator provide reagents the project, including immunogens purified protein immunogenic peptides), tagged cDNA expression constructs screening specificity testing monoclonal antibodies, positive control polyclonal antibodies available), knockout mouse tissue available).  Investigators encouraged participate screening resulting monoclonal antibodies facilitate selection the best clone(s).  resulting NeuroMabs be available low cost the neuroscience research community the NeuroMab Facility www.neuromab.org). Eligibility current announcement for administrative supplements participating IC-funded projects ($10K-$50K total costs, per project) design generation reagents antibody production validation, such immunogens e.g., fusion protein cDNA constructs purified fusion proteins), and/or tagged cDNA expression vectors antibody screening.  request include providing reagents multiple targets can include personnel costs.  requests equipment be considered.  Investigators Mentored Career Development K01, K08, K23, K25 K99/R00), Research Scientist K02 K24), Research Project R01 U01), Academic Research Enhancement R15), Exploratory/ Developmental R21), Phase II SBIR R44 U44), Program Project P01), Developing Center P20), Research Resource U24), Specialized Center P50 U54) grants eligible apply.  be eligible, projects must actively funded throughout fiscal year 2009.  Review criteria provided below.  be eligible, parent grant must active, the research proposed the supplement must accomplished within competitive segment. proposed supplement MUST within general scope the peer-reviewed activities aims approved within parent grant. IMPORTANT:  research proposed the NIH grantee the supplement application must within original scope the NIH-supported grant project.  funding mechanism being used support program, administrative supplements, be used cover cost increases are associated achieving certain new research objectives long they within original scope the project.  Any cost increases need result making modifications the project order take advantage opportunities would increase value the project consistent its originally approved objectives purposes. Investigators strongly encouraged contact NeuroMab Facility neuromab@ucdavis.edu) advance submitting supplement request preliminary discussions immunogens other reagents needed screening specificity testing. Submitting Application Applications an administrative supplement under program should the PHS 398 form rev. 11/2007; available http://grants.nih.gov/grants/funding/phs398/phs398.html), must include following: 1) cover letter citing Notice including PI name, grant number title, amount the requested supplement, name title the institutional official, the phone, email, address information both PI institutional official.  P01s, P20s, P50s, U24s U54s, PI must submit request a supplement one more subprojects.  cover letter must signed the PI the institutional official. 2) Face page title the project Box 1) should the title the parent award. Notice number title) should cited Box 2, the ldquo;yes” box should checked. Subproject PIs P01, P20, P50 U54 awards eligible apply these supplements. remaining items the face page should filled according the PHS 398 application instructions. 3) Form page 2 Project Summary, Relevance, Performance Sites, Scientific/Key Personnel, Significant Contributors, Human Embryonic Stem Cells) PHS 398. project description that the administrative supplement, the parent grant. 4) Proposed budget the supplement a budget justification details items requested.  Supplements should range 10,000 50,000.  awards TOTAL COSTS.  Any Facilities amp; Administrative Costs indirect costs) should included the modular request, cannot requested addition the modular amounts.  all grant mechanisms maximum supplement 50,000. 5) Biographical Sketch the PI. 6) Research Plan the supplement, items 2-5 to exceed five pages.  Applicants should include justification each nervous system target, relationship each target the original project Specific Aims, a discussion the significance having newly monoclonal antibodies available.  research design section should include plans each target provide expertise, immunogens purified protein suggested peptide sequences), tagged cDNA expression constructs screening specificity testing hybridomas, positive control polyclonal antibodies available) knockout mouse tissue available).  Font size restrictions apply designated within PHS398 rev. 11/2007) instructions. Review Criteria Applications be reviewed administratively.  Review criteria include 1) completeness the reagent package(s) be provided, 2) expertise the investigators their ability produce obtain proposed reagents, 3) importance the proposed antibodies the goals the funded project for areas developmental neuroscience, particularly those high relevance program priorities the Blueprint ICs.  is anticipated supplements be awarded before end the fiscal year. nbsp;  Budget Information Supplements be in amounts 10,000 to 50,000 total costs.  all grant mechanisms maximum supplement 50,000 total costs. Requests include providing reagents multiple targets can include personnel costs.  requests equipment be considered. nbsp; to Apply is one-time announcement.  Applications must received or before receipt date indicated Key Dates).  not send applications the Center Scientific Review.  Applicants should submit electronic copy the application an e-mail attachment PDF format NINDSNeuroDevMabsupplements@ninds.nih.gov, one hard copy original signatures the PI institutional official) to: Randall R. Stewart, Ph.D. NOT-NS-09-014 National Institute Neurological Disorders Stroke National Institutes Health Neuroscience Center, Room 2136 6001 Executive Blvd. Bethesda, MD 20892-9523 courier delivery:  Rockville, MD 20852). Inquiries Inquiries should directed to: Randall R. Stewart, Ph.D. Program Director Channels, Synapses Circuits SBIR/STTR Program Coordinator National Institute Neurological Disorders Stroke National Institutes Health Neuroscience Center, Room 2135 6001 Executive Blvd. Bethesda, MD 20892-9523 courier delivery:  Rockville, MD 20852) Phone:  301-496-1917 Fax:  301-402-1501 E-mail:  stewartr@ninds.nih.gov Laurie S. Nadler, Ph.D. Chief, Neuropharmacology Program Division Neuroscience Basic Behavioral Science National Institute Mental Health, NIH 6001 Executive Blvd., Rm. 7184, MSC 9641 Bethesda, MD 20892-9641 Rockville, MD 20852 express courier service] Phone:  301-443-5288 Fax:  301-451-5615 E-mail:  lnadler@mail.nih.gov Barry Davis, Ph.D. Director, Taste Smell Program National Institute Deafness Other Communication Disorders 6120 Executive Blvd, Suite 400 Bethesda MD 20892-7180 Phone:  301-402-3464 Fax:  301-402-6251 Email:  Davisb1@nidcd.nih.gov Matthew Reilly, Ph.D. Program Director, Genetics amp; Proteomics Division Neuroscience amp; Behavior, NIAAA 5635 Fishers Lane Room 2065, MSC 9304 Bethesda, MD 20892-9304 Phone: 301-594-6228     Fax: 301-443-1650 E-mail:  reillymt@mail.nih.gov nbsp;Nancy S. Pilotte, Ph.D., Chief Functional Neuroscience Research Branch Division Basic Neuroscience Behavioral Research National Institute Drug Abuse 6001 Executive Boulevard Room 4282, MSC 9555 Bethesda, MD 20892-9555 courier delivery: Rockville, MD  20852 Phone:  301-435-1317 Fax:  301-594-6043 E-mail:  npilotte@nih.gov James N. Coulombe, Ph.D. Health Scientist Administrator Developmental Biology, Genetics Teratology Center Developmental Biology Pediatric Medicine National Institute Child Health Human Development RM 4B01, MSC 7510 6100 Executive Blvd Bethesda, MD 20892-7510 Phone: 301-451-1390 Fax: 301-480-0303 E-mail:  CoulombeJ@mail.nih.gov